ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lamivudine

Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.

Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 15, 200049 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only352 open or runningphase 4since Feb 15, 2000Nov 2, 1999Sep 14, 2032phase 3 · NCT07393659
Bristol-Myers Squibbits history only70 open or runningphase 4since Jun 27, 2005Nov 2, 1999none ahead
Abbott40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Dupont Merckits history only20 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
triangle-pharmaceuticalsits history only10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbott only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 3 study in HIV InfectionsFirst studyNCT00004583 · 660 enrolled · United States, Australia, Austria and more
  2. May 29, 2002Phase 2 study in HIV InfectionsNCT00038220 · 40 enrolled · United States
  3. Aug 15, 2002Phase 2 study in HIV InfectionsNCT00043953 · 30 enrolled · United States, Canada
  4. Sep 13, 2005Phase 3 study in HIV InfectionsNCT00234923 · 138 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 4 Abbott leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00234923HIV Infections3CompletedFeb 2007138
NCT00043953HIV Infections · United States, Canada2Completed30
NCT00038220HIV Infections · United States2Completed40
NCT00004583HIV Infections · United States, Australia, Austria and more3Completed660

How it is read

Names in the registry

  • “Lamivudine”, 35 entries
  • “Lamivudine/Zidovudine”, 6 entries
  • “Lamivudine (3TC)”, 4 entries
  • “lamivudine”, 3 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.